Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease:A review of preliminary data,efficacy,and cost  

作　　者：Alan D.Workman Benjamin S.Bleier 

机构地区：[1]Department of Otolarynsology,Massachusetts Eye and Ear Infirmary,Harvard Medical School,Boston,M Af USA

出　　处：《World Journal of Otorhinolaryngology-Head and Neck Surgery》2020年第4期230-234,共5页世界耳鼻咽喉头颈外科杂志（英文）

摘　　要：Aspirin-exacerbated respiratory disease(AERD)patients with CRSwNP suffer from reduced quality of life,reduced economic productivity,and higher risk of depression and sleep dysfunction.These patients often require frequent medical and surgical therapy,including functional endoscopic sinus surgery for recalcitrant disease.Given this severity,anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP,including Omalizumab and Dupilumab.Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologies are comparable to the current standard of care in the short term,but there is a lack of long-term data and standardized regimen that makes direct comparison difficult.Biologic therapies additionally require continuous use to avoid recurrence,and currently cost many times more than existing medical or surgical therapies.

关 键 词：CRSwNP AERD BIOLOGICS OMALIZUMAB Dupilumab 

分 类 号：R765[医药卫生—耳鼻咽喉科] R562.25[医药卫生—临床医学]